http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Environmental Management in Industry
Han, Sang Wook,Kim, Ik Soo,Terence P. CURRAN 한국환경정책학회 1995 環境政策 Vol.3 No.1
환경문제를 야기시키는 원인은 인간 그 자체에 있으며, 경제주체별로는 개인, 기업, 정부로 볼 수 있다. 시시각각 변화하고 강화되여가는 국제환경질서에 대처하기 위해서는 기업과 정부가 협조적인 관계를 유지하면서 각각의 역할을 하여야하는 바, 기업은 사회공헌책임주의에 입각하여 환경친화책인 기업경영을 도입, 실천해야 하며, 정부는 이를 지원, 촉진하기 위한 정책을 펼쳐야 할 것이다. 이 논문은 지구차원에서의 환경문제, 미국과 한국의 최근 환경정책 그리고 기업에서의 환경경영도입의 중요성과 환경경영이 모든 조직기능에서 통합 고려되어야 하는 필요성올 논의하였으며, 기업의 환경경영을 위한 환경성과지표, 환경심사, 전과정분석 등의 요소들을 검토하였다. 끝으로 3M, Body Shop, Baxter International 둥 3개 기업에 있어서의 환경경영의 사례를 동해 환경경영에 의한 기업이익을 엿볼 수 있었다.
Moment ratio considering composite beam action for steel special moment frames
Sang Whan Han,Soo Ik Cho,Taeo Kim,Kihak Lee 국제구조공학회 2023 Steel and Composite Structures, An International J Vol.47 No.4
The strong column-weak beam (SCWB) moment ratio is specified in AISC 341 to prevent an abrupt column sway in steel special moment frames (SMFs) during earthquakes. Even when the SCWB requirement is satisfied for an SMF, a column-sway can develop in the SMF. This is because the contribution of the composite beam action developed in the concrete floor slab and its supporting beams was not included while calculating the SCWB moment ratio. In this study, we developed a new method for calculating the SCWB moment ratio that included the contribution of composite beam action. We evaluated the seismic collapse performance of the SMFs considering various risk categories and building heights. We demonstrated that the collapse performance of the SMFs was significantly improved by using the proposed SCWB equation that also satisfied the target performance specified in ASCE 7.
( Sung Hee Lim ),( Jong-mu Sun ),( Joohyun Hong ),( Dongryul Oh ),( Yong Chan Ahn ),( Man Ki Chung ),( Han-sin Jeong ),( Young-ik Son ),( Myung-ju Ahn ),( Chung-hwan Baek ),( Keunchil Park ) 대한내과학회 2021 The Korean Journal of Internal Medicine Vol.36 No.0
Background/Aims: Clinical trials have not consistently supported the use of induction chemotherapy (IC) for locally advanced head and neck squamous cell cancer. Hypopharynx and base of tongue (BOT) cancer has shown relatively poor survival. We investigated the role of IC in improving outcome over current chemoradiotherapy (CRT) in patients with hypopharynx and BOT cancer. Methods: Treatment-naïve patients with stage III/IV (M0) hypopharynx or BOT cancer were randomly assigned to receive CRT alone (CRT arm: cisplatin 100 mg/m<sup>2</sup> on D1 3-weekly, two times plus radiotherapy 68.4 Gy/30 fractions on weekdays) versus two 21-day cycles of IC with TPF (docetaxel & cisplatin 75 mg/m<sup>2</sup> on D1, and fluorouracil 75 mg/m<sup>2</sup> on D1-4) followed by the same CRT regimen (IC arm). The primary endpoint was progression-free survival (PFS). Results: This study closed early after enrollment of 36 patients (19 in the CRT arm, 17 in the IC arm). After a median follow-up of 47.2 months, there was no significant difference in PFS: the median PFS was 26.8 months for the CRT arm and was not reached for the IC arm (p = 0.13). However, the survival curves were widely separated with a plateau after 3 years, suggesting a potential survival benefit from IC: 3-year PFS rates were 45% and 68%, and 3-year overall survival rates were 56% and 86%, in the CRT and IC arms, respectively. Conclusions: This study failed to demonstrate that induction TPF chemotherapy improves survival in patients with BOT and hypopharynx cancer. However, it suggested a favorable outcome with IC to this population.
Optimal design of slotless-type PMLSM considering multiple responses by response surface methodology
Sung-Il Kim,Jung-Pyo Hong,Young-Kyoun Kim,Hyuk Nam,Han-Ik Cho IEEE 2006 IEEE transactions on magnetics Vol.42 No.4
<P>This paper shows the usefulness of response surface methodology (RSM) for optimal design considering multiple responses. Moreover, full factorial design, one of the experimental design methods, is proposed to establish more reasonable and objective design area for applying RSM. The slotless-type permanent-magnet linear synchronous motor is optimized to develop larger average thrust and lower thrust ripple than the prototype, and the optimally designed one is manufactured. In the end, all analysis results are obtained by space harmonic method for fast and efficient design, and the validity of the results is verified by comparison with finite-element analysis and test</P>
Subcutaneous toxicity of melittin-dKLA in ICR mice
Sung Jiham,Kim Yura,Yu Pei Fu,김연섭,Han Ik-Hwan,배현수 대한독성 유전단백체 학회 2021 Molecular & cellular toxicology Vol.17 No.4
Background Melittin, a major component of honeybee venom, is known to possess anti-allergic, anti-inflammatory, anti-arthritis, and anti-cancer. Despite its great promise as an agent for various diseases, the therapeutic applications of melittin have been severely limited by its nonspecific cytotoxicity and hemolytic activity. Objective We synthesized a hybrid peptide (melittin-dKLA), composed of melittin and the pro-apoptotic peptide (dKLA), and evaluated its potential toxicity in ICR mice following a single or repeated subcutaneous dose administration. Results Mice administered a single subcutaneous dose of melittin-dKLA showed no mortality or abnormal clinical signs in all animals. Similarly, mice administered a repeated subcutaneous dose of melittin-dKLA resulted in no deaths. Crust formation and induration were observed in the male and female mice in the 5 and 20 mg/kg, respectively. The hematological parameters and serum biochemical analysis did not show any changes by melittin-dKLA. In repeated subcutaneous dose study, the mice in the 20 mg/kg group showed a significant increase in the relative weight of the spleen compared to the control group. Although the difference was not statistically significant. Mice exhibited a common pattern of change. Conclusion Taken together, our results suggest that the toxicity of melittin-dKLA is higher than 20 mg/kg both as a single and a repeated subcutaneous administration in ICR mice. Thus, it is suggested that it will be an important data in the development of new drug for melittin-dKLA.